Companies/CA/RKV

RAKOVINA THERAPEUTICS INC.

Ownership & governance

Executives 5Directors 5Avg age 60Avg tenure 2.2y
Kim Oishi
Chief Executive Officer
Age 62Since 2026-01-26Profile →

Executives5

Kim Oishi
Chief Executive Officer
Age 62Since 2026-01-26
David Kideckel
Director of Finance/CFO
—Since 2025-04-30
Mads Daugaard
President
—Since 2020-12-31
John Langlands
Chief Operating Officer
—Since 2021-02-03
Michelle Seltenrich
Corporate Officer/Principal
—Since 2024-09-30

Board of directors5

Jeffrey Bacha
Chairman
Age 58Since 2020-11-30
Yevgeniy Meshcherekov
Director/Board Member
Age 49Since 2025-04-28
David Kideckel
Director/Board Member
—Since 2025-04-28
Kim Oishi
Director/Board Member
Age 62Since 2026-01-26
Frank Holler
Director/Board Member
Age 69Since 2026-01-26

Shareholders5

NameStakeShares
NewGen Therapeutics, Inc.
11.47 %
2,426,562
Jeffrey Bacha
1.208 %
255,555
Alfredo de Lucrezia
0.7767 %
164,250
Dennis Brown
0.2955 %
62,500
David Kideckel
0.0946 %
20,000

Catalog · 2026-07-09

Registry officers10

NameRoleSinceShares
David KideckelDirector of Finance/CFO2025-04-30-
Jeffrey BachaChairman2020-11-30-
John LanglandsChief Operating Officer2021-02-03-
Kim OishiChief Executive Officer2026-01-26-
David KideckelDirector/Board Member2025-04-28-
Frank HollerDirector/Board Member2026-01-26-
Kim OishiDirector/Board Member2026-01-26-
Yevgeniy MeshcherekovDirector/Board Member2025-04-28-

Registry · as of 2026-07-09

Institutional (13F)

Loading Form 13F holders…

Fund membership

Loading fund baskets…

Street consensus

Consensus noneMean target 0.25Range 0.25–0.25Analysts 1
  • Hold 1

Firm rows and rating mix from Yahoo Finance; mean target is Yahoo’s aggregate until OpenFilings derives consensus from broker rows.

Peers